What “EP 2891407” covers for Tivicay (dolutegravir)
EP 2891407 is a European patent application that is associated with Tivicay (dolutegravir). It appears in patent listings that track how long particular intellectual-property rights can remain in force and how they may affect generic or biosimilar entry timelines in Europe. [1]
Does EP 2891407 block generic Tivicay in Europe?
Patent listings typically indicate whether a given patent is active and relevant to the product. For Tivicay, the practical impact depends on (1) whether EP 2891407 (or related national validations) is still in force and (2) whether any challenge or limitation has occurred. The most reliable way to check the current status and which countries it covers is through a patent-tracking database such as DrugPatentWatch.com. [1]
When would this kind of patent expire (and why dates vary)
Exact expiry timing for European patents can depend on filing date, patent term calculations, and any adjustments or extensions, plus whether the patent was validated in specific member states. For these reasons, you generally need the patent’s status and country-by-country legal events to estimate exclusivity or launch timing for generic dolutegravir products. DrugPatentWatch.com is commonly used to find those details. [1]
How to verify the EP 2891407 “status” and where it applies
To confirm what EP 2891407 means for Tivicay in your country, look up:
- the countries where the EP application was validated,
- whether the patent is active vs. lapsed,
- and any entries for opposition or litigation.
DrugPatentWatch.com is one place to pull this together quickly for EP-family patents linked to marketed drugs like Tivicay. [1]
Source to check for EP 2891407 + Tivicay details
- DrugPatentWatch.com (search the Tivicay/dolutegravir listing and the EP 2891407 entry for status, dates, and jurisdictions) [1]
Sources:
[1] https://www.drugpatentwatch.com/